CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Cash Flow Y/Y Annual
Idexx Laboratories Inc  (IDXX)
Other Ticker:  
 
 

IDXX's Net Cash Flow Growth by Quarter and Year

Idexx Laboratories Inc's Net Cash Flow results by quarter and year




IDXX Net Cash Flow (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 122.24 13.37 -0.75
III Quarter September - 198.86 -15.19 -86.93
II Quarter June 4.16 21.47 -90.26 -119.03
I Quarter March -56.50 -1.18 60.16 -32.77
FY   -52.34 341.39 -31.92 -239.48



IDXX Net Cash Flow second quarter 2024 Y/Y Growth Comment
Idexx Laboratories Inc reported drop in Net Cash Flow in the second quarter 2024 by -80.64% to $ 4.16 millions, from the same quarter in 2023.
Despite modest results in the second quarter 2024, contraction in Idexx Laboratories Inc's Net Cash Flow appears to be smaller than Company's recent average decline.

According to the results reported in the second quarter 2024, Idexx Laboratories Inc achieved the best Net Cash Flow growth in In Vitro & In Vivo Diagnostic Substances industry. While Idexx Laboratories Inc' s Net Cash Flow meltdown of -80.64% ranks overall at the positon no. 46 in the second quarter 2024.


IDXX Net Cash Flow ( Y/Y Growth %) 2024
 2023 2022 2021
IV Quarter December - 814.29 % - -
III Quarter September - - - -
II Quarter June -80.64 % - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Idexx Laboratories Inc's second quarter 2024 Net Cash Flow $ 4.16 millions IDXX's Income Statement
Idexx Laboratories Inc's second quarter 2023 Net Cash Flow $ 21.47 millions Quarterly IDXX's Income Statement
New: More IDXX's historic Net Cash Flow Growth >>


IDXX Net Cash Flow (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
IV Quarter December - -38.53 % - -
III Quarter September - 826.22 % - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -


Go to IDXX Cash flow Statement >> Back to IDXX Growth rate Comparisons >>


Net Cash Flow second quarter 2024 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #1
Healthcare Sector #13
Overall #46

Net Cash Flow Y/Y Growth Statistics
High Average Low
1354.6 % -169.53 % -545.15 %
(Jun 30 2024)   (Dec 31 2015)
Net Cash Flow second quarter 2024 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #1
Healthcare Sector #13
Overall #46
Net Cash Flow Y/Y Growth Statistics
High Average Low
1354.6 % -169.53 % -545.15 %
(Jun 30 2024)   (Dec 31 2015)

Net Cash Flow by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Idexx Laboratories Inc's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IDXX's II. Quarter Q/Q Net Cash Flow Comment
II. Quarter 2024Cyclical Idexx Laboratories Inc in the influence net cash outflow of $ 4.16 millionsCyclical influence seem to have led to Idexx Laboratories Inc's restoration of profitability, as IDXX clinchesNet Cash Flow of $ 4.16 millions in the II. Quarter 2024 emerging from net cash outflow-56.50 millions in the first quarter. Idexx Laboratories Inc announced in the II. Quarter 2024 Net Cash Flow of $ 4.16 millions compare to net cash outflow recorded in previos quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Idexx Laboratories Inc achieved highest sequential Net Cash Flow growth. While Idexx Laboratories Inc's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IDXX's II. Quarter Q/Q Net Cash Flow Comment
II. Quarter 2024Cyclical Idexx Laboratories Inc in the factors net cash outflow of $ 4.16 millionsCyclical factors seem to have contributed Idexx Laboratories Inc's restoration of recovery, as IDXX postNet Cash Flow of $ 4.16 millions in the II. Quarter 2024 coming of net cash outflow-56.50 millions in the first quarter. Idexx Laboratories Inc announced in the II. Quarter 2024 Net Cash Flow of $ 4.16 millions compare to net cash outflow recorded in previos quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Idexx Laboratories Inc achieved highest sequential Net Cash Flow growth. While Idexx Laboratories Inc's Net Cash Flow growth quarter on quarter, overall rank is .


Idexx Laboratories Inc's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Net Cash Flow 12 Months Ending $ 268.75 $ 286.07 $ 341.39 $ 232.52 $ 18.48
Y / Y Net Cash Flow Growth (TTM) 1354.6 % - - - -
Year on Year Net Cash Flow Growth Overall Ranking # 40 # 0 # 0 # 0 # 0
Seqeuential Net Cash Flow Change (TTM) -6.05 % -16.2 % 46.82 % 1158.5 % -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # 46 # 59 # 41 # 47 # 0

New: More IDXX's historic Net Cash Flow Growth >>



Cumulative Net Cash Flow growth Comment
With 1354.6% annual Net Cash Flow growth, Idexx Laboratories Inc would report a record annual Net Cash Flow surge if the fiscal year would end on Jun 30 2024.

Among companies within the Healthcare sector 9 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Net Cash Flow growth total ranking has deteriorated compare to previous quarter from 0 to 40.

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
1354.6 %
-169.53 %
-545.15 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 1
Healthcare Sector # 10
Overall # 40

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
1354.6 %
-169.53 %
-545.15 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 13
S&P 500 # 46
Cumulative Net Cash Flow growth Comment
With 1354.6% annual Net Cash Flow growth, Idexx Laboratories Inc would report a record annual Net Cash Flow surge if the fiscal year would end on Jun 30 2024.

Among companies within the Healthcare sector 9 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Net Cash Flow growth total ranking has deteriorated compare to previous quarter from 0 to 40.

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
1354.6 %
-169.53 %
-545.15 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 1
Healthcare Sector # 10
Overall # 40

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
1354.6 %
-169.53 %
-545.15 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 13
S&P 500 # 46




Other Net Cash Flow Growth
In Vitro & In Vivo Diagnostic Substances Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
IDXX's Net Cash Flow Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for IDXX's Competitors
Net Cash Flow Growth for Idexx Laboratories Inc's Suppliers
Net Cash Flow Growth for IDXX's Customers

You may also want to know
IDXX's Annual Growth Rates IDXX's Profitability Ratios IDXX's Asset Turnover Ratio IDXX's Dividend Growth
IDXX's Roe IDXX's Valuation Ratios IDXX's Financial Strength Ratios IDXX's Dividend Payout Ratio
IDXX's Roa IDXX's Inventory Turnover Ratio IDXX's Growth Rates IDXX's Dividend Comparisons



Companies with similar Net Cash Flow surge for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Jun 30 2024
Teladoc Health Inc -5.93%$ -5.929 millions
Maxcyte inc -8.73%$ -8.727 millions
Amedisys Inc-12.86%$ -12.855 millions
Radnet Inc -19.23%$ -19.227 millions
P3 Health Partners Inc -19.66%$ -19.657 millions
Soligenix inc -19.83%$ -19.830 millions
Quoin Pharmaceuticals Ltd -27.08%$ -27.080 millions
Prothena Corporation Public Limited Company-32.87%$ -32.871 millions
Globus Medical Inc -36.51%$ -36.506 millions
Electromedical Technologies inc -39.13%$ -39.133 millions
Inovio Pharmaceuticals Inc -39.57%$ -39.567 millions
Vericel Corporation-43.09%$ -43.093 millions
Bionano Genomics Inc -47.23%$ -47.228 millions
Innovage Holding Corp-48.57%$ -48.566 millions
Inspire Medical Systems inc -49.36%$ -49.360 millions
Coeptis Therapeutics Holdings Inc -53.79%$ -53.793 millions
Bio techne Corp-59.36%$ -59.356 millions
Matinas Biopharma Holdings Inc -63.24%$ -63.237 millions
Microbot Medical Inc -63.50%$ -63.501 millions
Gri Bio Inc -67.25%$ -67.246 millions
-72.85%$ -72.851 millions
Encompass Health Corporation-72.91%$ -72.911 millions
Axogen inc -77.59%$ -77.592 millions
Denali Therapeutics Inc -77.93%$ -77.932 millions
Enzon Pharmaceuticals inc -78.19%$ -78.190 millions
Artivion Inc -78.33%$ -78.330 millions
Geovax Labs Inc -78.93%$ -78.930 millions
Tg Therapeutics Inc -79.08%$ -79.079 millions
Idexx Laboratories Inc-80.64%$ -80.639 millions
Caredx Inc -81.14%$ -81.137 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com